Clinical trials: Real World Data in China
Pulmonary Fibrosis
Safety of Nintedanib in Real World in China
The main objective of this study is to evaluate the incidence rates of adverse drug reactions (ADRs) and fatal adverse events (AEs) among idiopathic pulmonary fibrosis (IPF) patients in China who initiate nintedanib during the…
- Trial name
- NCT05676112
- Testing
- nintedanib, pirfenidone
- Sponsor
- Boehringer Ingelheim
Real World Data in China
Trevo® Retriever Registry (China)
Trevo® Retriever Registry (China) is to assess real world performance of the FDA cleared Trevo Retriever intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke in…
- Trial name
- NCT03554850
- Testing
- Trevo® Retriever
- Where
- 10 sites in China
- Volunteers
- 201 people
- Sponsor
- Stryker Neurovascular
Breast Cancer
A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.
The study aims to describe demographics, clinical characteristics, genetic test diagnosis, treatment patterns, and clinical outcomes in HR+/HER2- (including HER2-low, HER2-ultralow, and HER2-null) unresectable or metastatic…
- Trial name
- VERITAS (NCT07743944)
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Crohn Disease
A Retrospective Observational Study of Ustekinumab Among Bio-naive Participants With Crohn's Disease in China
Bio-naive participants are defined as the participants who previously have not received any biologics for Crohn's Disease (CD).The purpose of this retrospective study is to describe the endoscopic remission at week 24 among…
- Trial name
- NCT06082986
- Testing
- Ustekinumab
- Where
- 3 sites in China
- Volunteers
- 200 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Non-small Cell Lung Cancer (NSCLC)
A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)
The main aim of this study is to learn about the time between the start and stop of treatment with brigatinib in Chinese participants with non-small-cell lung cancer (NSCLC) and who have been positively diagnosed with having the…
- Trial name
- Brilliant (NCT05721950)
- Testing
- Brigatinib
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Takeda